

NA Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2022-11-01 | 221 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

The North America lung cancer diagnostics market is projected to register a substantial CAGR of 14.6% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030

Market Segmentation:

North America Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of the North America lung cancer diagnostics market are:

- Rise in prevalence and incidence of lung cancer
- Increase in healthcare expenditure for better health services

Market Players:

Some of the major players operating in the North America lung cancer diagnostics market are:

- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Abbott
- Quest Diagnostics Incorporated
- Biodesix
- Bio-Rad Laboratories, Inc.
- Biocartis
- Danaher
- DiaSorin S.p.A.
- Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 20/20 Gene Systems
- Guardant Health, Inc.
- Inivata Ltd.
- Vela Diagnostics
- LalPathLabs.com
- LungLife AI, Inc.
- Myriad Genetics, Inc.
- NeoGenomics Laboratories
- NanoString
- Oncocyte Corporation
- PerkinElmer Inc.
- QIAGEN
- Siemens Healthcare GmbH
- Veracyte, Inc.

Table of Contents:

TABLE OF CONTENTS	
1 INTRODUCTION	52
1.1 OBJECTIVES OF THE STUDY	52
1.2 MARKET DEFINITION	52
1.3 OVERVIEW OF NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET	52
1.4 LIMITATIONS	54
1.5 MARKETS COVERED	54
2 MARKET SEGMENTATION	57
2.1 MARKETS COVERED	57
2.2 GEOGRAPHICAL SCOPE	58
2.3 YEARS CONSIDERED FOR THE STUDY	59
2.4 CURRENCY AND PRICING	59
2.5 DBMR TRIPOD DATA VALIDATION MODEL	60
2.6 MULTIVARIATE MODELLING	63
2.7 PRODUCT TYPE LIFELINE CURVE	63
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS	65
2.9 DBMR MARKET POSITION GRID	66
2.10 MARKET TESTING TYPE COVERAGE GRID	68
2.11 VENDOR SHARE ANALYSIS	69
2.12 SECONDARY SOURCES	70
2.13 ASSUMPTIONS	70
3 EXECUTIVE SUMMARY	71
4 PREMIUM INSIGHTS	74
4.1 PORTER'S FIVE FORCES	75
4.2 PESTEL ANALYSIS	76
4.3 INDUSTRY INSIGHTS	77
5 EPIDERMIOLOGY	78
6 REGULATIONS	79

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7 MARKET OVERVIEW	82
7.1 DRIVERS	84
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION	84
7.1.2 INCREASING EARLY DIAGNOSIS OF LUNGS CANCER	85
7.1.3 INCREASING CASES OF LUNG CANCER	87
7.1.4 RISE IN PRODUCT APPROVALS	87
7.2 RESTRAINTS	89
7.2.1 POOR & LATE DIAGNOSIS OF LUNG CANCER	89
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY	89
7.3 OPPORTUNITIES	91
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT	91
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS	91
7.3.3 RISING AWARENESS OF LUNG CANCER	92
7.4 CHALLENGES	93
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS	93
7.4.2 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES	93
7.4.3 LACK OF SKILLED AND CERTIFIED PROFESSIONALS	94
8 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE	95
8.1 OVERVIEW	96
8.2 INSTRUMENTS	99
8.2.1 IMAGING INSTRUMENTS	100
8.2.1.1 CT SYSTEMS	100
8.2.1.2 ULTRASOUND SYSTEMS	100
8.2.1.3 MRI SYSTEMS	100
8.2.1.4 OTHERS	100
8.2.2 BIOPSY INSTRUMENTS	101
8.2.2.1 NEEDLE BIOPSY	101
8.2.2.2 ENDOSCOPIC BIOPSY	101
8.2.2.3 CORE BIOPSY	101
8.2.2.4 OTHERS	101
8.2.3 PATHOLOGY-BASED INSTRUMENTS	102
8.2.3.1 SLIDE STAINING SYSTEMS	102
8.2.3.2 TISSUE PROCESSING SYSTEMS	102
8.2.3.3 CELL PROCESSORS	102
8.2.3.4 PCR INSTRUMENTS	102
8.2.3.5 OTHERS PATHOLOGY-BASED INSTRUMENTS	102
8.3 CONSUMABLES AND ACCESSORIES	103
8.3.1 KITS	104
8.3.1.1 DNA POLYMERASE KITS	104
8.3.1.2 NUCLEIC ACID ISOLATION KITS	104
8.3.1.3 PCR KITS	104
8.3.1.4 OTHERS	104
8.3.2 REAGENTS	105
8.3.2.1 ASSAYS	105
8.3.2.2 BUFFERS	105
8.3.2.3 PRIMERS	105

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

8.3.2.4 OTHERS	105
8.3.3 PROBES	106
8.3.4 OTHER CONSUMABLES	106
9 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE	107
9.1 OVERVIEW	108
9.2 IMAGING TEST	111
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN	112
9.2.2 POSITRON EMISSION TOMOGRAPHY (PET) SCAN	112
9.2.3 CHEST X-RAY	112
9.2.4 BONE SCAN	112
9.2.5 MRI	112
9.2.6 OTHERS	112
9.3 BIOMARKERS TEST	113
9.3.1 EGFR MUTATION TEST	114
9.3.2 KRAS MUTATION TEST	114
9.3.3 ALK TEST	114
9.3.4 HER2 TEST	114
9.3.5 OTHERS	115
9.4 BIOPSY	115
9.4.1 NEEDLE BIOPSY	116
9.4.2 BRONCHOSCOPY BIOPSY	116
9.4.3 CORE BIOPSY	116
9.4.4 OTHERS	116
9.5 BLOOD TEST	116
9.5.1 COMPLETE BLOOD COUNT (CBC)	117
9.5.2 BLOOD CHEMISTRY TESTS	117
9.5.3 OTHERS	117
9.6 OTHERS	118
10 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE	119
10.1 OVERVIEW	120
10.2 NON-SMALL CELL LUNG CANCER	123
10.3 SMALL CELL LUNG CANCER	124
11 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER	125
11.1 OVERVIEW	126
11.2 HOSPITAL	129
11.3 ASSOCIATED LABS	129
11.4 INDEPENDENT DIAGNOSTIC LABORATORIES	130
11.5 DIAGNOSTIC IMAGING CENTERS	131
11.6 CANCER RESEARCH INSTITUTES	131
11.7 OTHERS	132
12 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL	133
12.1 OVERVIEW	134
12.2 DIRECT TENDER	137
12.3 RETAIL SALES	138
13 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY REGION	139
13.1 NORTH AMERICA	140
13.1.1 U.S.	149

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1.2 CANADA	154
13.1.3 MEXICO	159
14 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE	164
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA	164
15 SWOT ANALYSIS	165
16 COMPANY PROFILE	166
16.1 F. HOFFMANN-LA ROCHE LTD. (2022)	166
16.1.1 COMPANY SNAPSHOT	166
16.1.2 REVENUE ANALYSIS	166
16.1.3 COMPANY SHARE ANALYSIS	167
16.1.4 PRODUCT PORTFOLIO	167
16.1.5 RECENT DEVELOPMENTS	167
16.2 THERMO FISHER SCIENTIFIC INC. (2022)	168
16.2.1 COMPANY SNAPSHOT	168
16.2.2 REVENUE ANALYSIS	168
16.2.3 COMPANY SHARE ANALYSIS	169
16.2.4 PRODUCT PORTFOLIO	169
16.2.5 RECENT DEVELOPMENTS	169
16.3 ABBOTT (2022)	170
16.3.1 COMPANY SNAPSHOT	170
16.3.2 REVENUE ANALYSIS	170
16.3.3 COMPANY SHARE ANALYSIS	171
16.3.4 PRODUCT PORTFOLIO	171
16.3.5 RECENT DEVELOPMENTS	171
16.4 QUEST DIAGNOSTICS INCORPORATED (2022)	172
16.4.1 COMPANY SNAPSHOT	172
16.4.2 REVENUE ANALYSIS	172
16.4.3 COMPANY SHARE ANALYSIS	173
16.4.4 PRODUCT PORTFOLIO	173
16.4.5 RECENT DEVELOPMENTS	175
16.5 BIODESIX (2022)	176
16.5.1 COMPANY PROFILE	176
16.5.2 REVENUE ANALYSIS	176
16.5.3 COMPANY SHARE ANALYSIS	177
16.5.4 PRODUCT PORTFOLIO	177
16.5.5 RECENT DEVELOPMENTS	177
16.6 AMOY DIAGNOSTICS CO., LTD. (2022)	178
16.6.1 COMPANY SNAPSHOT	178
16.6.2 PRODUCT PORTFOLIO	178
16.6.3 RECENT DEVELOPMENTS	178
16.7 BIO-RAD LABORATORIES, INC. (2022)	179
16.7.1 COMPANY SNAPSHOT	179
16.7.2 REVENUE ANALYSIS	179
16.7.3 PRODUCT PORTFOLIO	180
16.7.4 RECENT DEVELOPMENTS	180
16.8 BIOCARTIS (2022)	181
16.8.1 COMPANY SNAPSHOT	181

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.8.2 REVENUE ANALYSIS	181
16.8.3 PRODUCT PORTFOLIO	182
16.8.4 RECENT DEVELOPMENTS	182
16.9 BODITECH MED INC.	183
16.9.1 COMPANY PROFILE	183
16.9.2 PRODUCT PORTFOLIO	183
16.9.3 RECENT DEVELOPMENTS	183
16.10 DANAHER (2022)	184
16.10.1 COMPANY SNAPSHOT	184
16.10.2 REVENUE ANALYSIS	184
16.10.3 PRODUCT PORTFOLIO	185
16.10.4 RECENT DEVELOPMENTS	185
16.11 DIASORIN S.P.A. (2022)	186
16.11.1 COMPANY SNAPSHOT	186
16.11.2 REVENUE ANALYSIS	186
16.11.3 PRODUCT PORTFOLIO	187
16.11.4 RECENT DEVELOPMENTS	187
16.12 EXACT SCIENCES UK, LTD. (SUBSIDIARY OF EXACT SCIENCE CORPORATION) (2022)	188
16.12.1 COMPANY SNAPSHOT	188
16.12.2 REVENUE ANALYSIS	188
16.12.3 PRODUCT PORTFOLIO	189
16.12.4 RECENT DEVELOPMENTS	189
16.13 20/20 GENE SYSTEMS	190
16.13.1 COMPANY PROFILE	190
16.13.2 PRODUCT PORTFOLIO	190
16.13.3 RECENT DEVELOPMENTS	190
16.14 GUARDANT HEALTH INC.	191
16.14.1 COMPANY PROFILE	191
16.14.2 PRODUCT PORTFOLIO	191
16.14.3 RECENT DEVELOPMENTS	191
16.15 INIVATA LTD.	192
16.15.1 COMPANY PROFILE	192
16.15.2 PRODUCT PORTFOLIO	192
16.15.3 RECENT DEVELOPMENTS	192
16.16 LALPATHLABS.COM (2022)	193
16.16.1 COMPANY SNAPSHOT	193
16.16.2 REVENUE ANALYSIS	193
16.16.3 PRODUCT PORTFOLIO	194
16.16.4 RECENT DEVELOPMENTS	195
16.17 LUNGLIFE AI, INC. (2022)	196
16.17.1 COMPANY SNAPSHOT	196
16.17.2 PRODUCT PORTFOLIO	196
16.17.3 RECENT DEVELOPMENTS	196
16.18 MEDGENOME	197
16.18.1 COMPANY SNAPSHOT	197
16.18.2 PRODUCT PORTFOLIO	197
16.18.3 RECENT DEVELOPMENTS	198

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.19 MYRIAD GENETICS, INC.	199
16.19.1 COMPANY SNAPSHOT	199
16.19.2 PRODUCT PORTFOLIO	199
16.19.3 RECENT DEVELOPMENTS	199
16.20 NEOGENOMICS LABORATORIES (2022)	200
16.20.1 COMPANY SNAPSHOT	200
16.20.2 REVENUE ANALYSIS	200
16.20.3 PRODUCT PORTFOLIO	201
16.20.4 RECENT DEVELOPMENTS	201
16.21 NANOSTRING (2022)	202
16.21.1 COMPANY SNAPSHOT	202
16.21.2 REVENUE ANALYSIS	202
16.21.3 PRODUCT PORTFOLIO	203
16.21.4 RECENT DEVELOPMENTS	203
16.22 NANOENTEK	204
16.22.1 COMPANY PROFILE	204
16.22.2 PRODUCT PORTFOLIO	204
16.22.3 RECENT DEVELOPMENTS	204
16.23 ONCOCYTE CORPORATION	205
16.23.1 COMPANY PROFILE	205
16.23.2 SERVICE PORTFOLIO	205
16.23.3 RECENT DEVELOPMENTS	205
16.24 PERKINELMER INC	206
16.24.1 COMPANY PROFILE	206
16.24.2 REVENUE ANALYSIS	206
16.24.3 PRODUCT PORTFOLIO	207
16.24.4 RECENT DEVELOPMENTS	207
16.25 PLEXBIO	208
16.25.1 COMPANY SNAPSHOT	208
16.25.2 PRODUCT PORTFOLIO	208
16.25.3 RECENT DEVELOPMENTS	208
16.26 QIAGEN	209
16.26.1 COMPANY SNAPSHOT	209
16.26.2 REVENUE ANALYSIS	209
16.26.3 PRODUCT PORTFOLIO	210
16.26.4 RECENT DEVELOPMENTS	210

NA Lung Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Market Report | 2022-11-01 | 221 pages | Data Bridge Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-07"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com